The CAR-TCR Summit was held in Boston, MA from September 4-7, 2018. Nuvera was proud to be both a sponsor and presenter at this year’s conference. Additionally, we had the opportunity to meet Emily Whitehead – the first child in the world to have her immune cells trained to fight cancer. Today, she is five years cancer-free. It is exciting to be an active participant in helping to bring this new technology to patients – science that will change peoples’ lives.
Greg Christianson, Principal at Nuvera, gave a talk focused on ‘Breaking the Traditional Clinical to Commercial Mindset – Understanding the implications of your clinical CAR-TCR-T trial experience on commercial uptake.’ The essence of the presentation centered around the opportunity CAR/TCR-T clinical trials provide to establish foundational elements required for a future commercial experience. This becomes especially important as the therapy’s ease of use and seamless experience, beyond clinical/safety performance, will be a critical differentiator, particularly:
- How easy is it to order and understand the status of the product
- How well are treatment sites educated and supported
- What systems are being leveraged to seamlessly coordinate sites
With an extensive number of stakeholders involved in CAR-T therapy and a significant number of different activities to coordinate, there is a high risk for a disjoint treatment experience. Greg highlighted three critical efforts all CAR/TCR-T teams should be focused on initially:
- Developing a holistic view of the end-to-end treatment experience (both clinical and commercial)
- Crystalizing a purposeful treatment experience and enabling principles
- Identifying and preparing for underlying system requirements
Based on a number of conversations with conference attendees the need for a different approach to customer experience management was well received.
Overall, the conference focused on three main themes:
- Transport, Logistics & Supply Chain
- Discovery / Translation
There was significant acknowledgement around the complexity of operations. So, in addition to focusing on typical clinical trial execution, it is critical to focus pre-approval resources on shortening the manufacturing timeline and ensuring proper management of the broad ecosystem.
It has been 6 years from proof of concept to commercialization but we are just at the foothills of where we are going with so many questions and so many opportunities. As this technology continues to advance, Nuvera is excited to work with Pharma/Biotech companies to ensure the patient / HCP experience is exceptional.
Nuvera dedicates itself to helping specialty pharmaceutical, biotech and rare disease companies to design and deliver a seamless patient and HCP experience for specialty therapies. Over the last 8 years, Nuvera has helped over 15 pharmaceutical companies to create and implement leading Patient-Centric solutions across 24 specialty therapeutic areas that received over 10 U.S. and Global excellence awards.
Nuvera services include the following:
• Uncover and crystalize patient and healthcare provider (HCP) needs
• Design impactful patient/HCP support experiences
• Build patient support programs and capabilities
• Optimize program performance
To learn more, please visit www.nuveracg.com